Drug intelligence / Profile preview

IO-0001

Development stage: Discontinued
Lead developer: Orum Therapeutics
Modality: Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

IO-0001 is an immune stimulating antibody conjugate (ISAC) that was initially developed by Orum Therapeutics. The drug was designed for the treatment of neoplasms (cancers). As an ISAC, it likely functions by combining the targeting specificity of antibodies with immune-stimulating payloads to enhance anti-tumor immune responses. However, specific details about its molecular target or mechanism of action have not been disclosed publicly. The development of IO-0001 has been discontinued and it is no longer in active clinical development[1].

Brand names: IO-0001IO0001IO 0001
Other names: IO-0001IO0001IO 0001

Beyond the preview

Go deeper on IO-0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IO-0001.

Explore the full profile